Scarica l'app Stockscreener
43.19
2.05%
-0.865
Precedente Chiudi:
$44.05
Aprire:
$44.05
Volume 24 ore:
18,846
Relative Volume:
0.05
Capitalizzazione di mercato:
$2.79B
Reddito:
$87.56M
Utile/perdita netta:
$-167.47M
Rapporto P/E:
-15.65
EPS:
-2.76
Flusso di cassa netto:
$-148.20M
1 W Prestazione:
-6.09%
1M Prestazione:
-7.33%
6M Prestazione:
+22.16%
1 anno Prestazione:
+127.56%
Intervallo 1D:
$42.91
$44.80
Intervallo di 1 settimana:
$41.12
$45.45
Portata 52W:
$18.89
$53.27
Kymera Therapeutics Inc Stock (KYMR) Company Profile
Nome
Kymera Therapeutics Inc
Settore
Industria
Telefono
857-285-5314
Indirizzo
500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN
Confronta KYMR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| KYMR | 43.01 | 2.79B | 87.56M | -167.47M | -148.20M | -2.76 |
| VRTX | 446.87 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 741.28 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.30 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 249.22 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.67 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Kymera Therapeutics Inc Stock (KYMR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-30 | Iniziato | Truist | Buy |
| 2023-05-05 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2022-12-06 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-11-08 | Iniziato | Raymond James | Mkt Perform |
| 2022-08-15 | Iniziato | Jefferies | Buy |
| 2022-08-03 | Iniziato | Goldman | Buy |
| 2022-07-20 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | JP Morgan | Neutral |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2021-09-30 | Iniziato | B. Riley Securities | Neutral |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-12-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-09-15 | Iniziato | BofA Securities | Neutral |
| 2020-09-15 | Iniziato | Cowen | Outperform |
| 2020-09-15 | Iniziato | Guggenheim | Buy |
| 2020-09-15 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie
Stephens Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Stephens - MarketBeat
US Bancorp DE Sells 651 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
Stephens & Co. Initiates Coverage of Kymera Therapeutics (KYMR) with Overweight Recommendation - MSN
Kymera Therapeutics (NASDAQ:KYMR) Shares Down 6.7%Here's What Happened - MarketBeat
Avoro Capital Advisors LLC Expands Stake in Kymera Therapeutics Inc - GuruFocus.com
Long Term Trading Analysis for (KYMR) - Stock Traders Daily
FMR LLC Bolsters Stake in Kymera Therapeutics Inc - GuruFocus.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $51.21 Average Price Target from Analysts - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $49.00 at Morgan Stanley - Defense World
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Target Price at $51.21 - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Kymer - GuruFocus.com
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q3 2024 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics to Participate in Upcoming November Investor Conferences - The Manila Times
Kymera Therapeutics to Present at 5 Major Healthcare Investor Conferences in November | KYMR Stock News - StockTitan
Mirae Asset Global Investments Co. Ltd. Boosts Stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World
UBS Group Has Lowered Expectations for Kymera Therapeutics (NASDAQ:KYMR) Stock Price - MarketBeat
Immunology to take front seat at Kymera - The Pharma Letter
Earnings call: Kymera Therapeutics advances in immunology and oncology By Investing.com - Investing.com Australia
Earnings call: Kymera Therapeutics advances in immunology and oncology - Investing.com India
Earnings Update: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Analysts Have Made A Financial Statement On Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Third-Quarter Report - Yahoo Finance
FY2024 Earnings Estimate for KYMR Issued By Leerink Partnrs - Defense World
Leerink Partnrs Issues Optimistic Estimate for KYMR Earnings - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
(KYMR) Long Term Investment Analysis - Stock Traders Daily
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates - MSN
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus - MSN
Guggenheim Increases Kymera Therapeutics (NASDAQ:KYMR) Price Target to $52.00 - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results - MarketBeat
The Latest Analyst Ratings For Kymera Therapeutics - Benzinga
Kymera Therapeutics (NASDAQ:KYMR) Receives "Buy" Rating from Truist Financial - MarketBeat
Kymera Therapeutics Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance UK
B.Riley boosts Kymera stock target amid cautious optimism for STAT6 degrader - Investing.com Australia
Kymera Therapeutics stock target lifted by Stifel, buy rating on oncology pivot - Investing.com UK
Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo Finance
Kymera Therapeutics Reports Q3 2024 Earnings and Strategic Shift - TipRanks
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap DownWhat's Next? - MarketBeat
Kymera Therapeutics (KYMR) Q3 2024 Earnings: EPS Misses at -$0.8 - GuruFocus.com
Kymera Therapeutics Announces Third Quarter 2024 Financial Results and Provides a Business Update - The Manila Times
Kymera Therapeutics Inc (KYMR) Q3 2024: Everything You Need To K - GuruFocus.com
Preview: Kymera Therapeutics's Earnings - Benzinga
Insights Ahead: Kymera Therapeutics's Quarterly Earnings - Benzinga
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Kymera Therapeutics (KYMR) Scheduled to Post Earnings on Thursday - MarketBeat
Kymera Therapeutics Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases - StockTitan
Kymera Therapeutics to Report Third Quarter 2024 Financial Results on October 31 - ForexTV.com
Kymera Therapeutics Announces Three Scientific Presentations at the EORTC-NCI-AACR 2024 Symposium - The Manila Times
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decrease in Short Interest - Defense World
Kymera Therapeutics (NASDAQ:KYMR) Trading 6.8% HigherStill a Buy? - MarketBeat
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Sees Significant Decline in Short Interest - MarketBeat
Kymera Therapeutics Inc Azioni (KYMR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):